790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

Research output: Contribution to journalMeeting abstract (Journal)

Original languageEnglish
JournalJournal for immunotherapy of cancer
Issue numberSuppl 2
Publication statusPublished - 7 Nov 2022
EventSITC Annual Meeting 2022 - Boston Convention Center, Boston, United States
Duration: 10 Nov 202212 Nov 2022

Cite this